tiprankstipranks
Carl Zeiss Meditec (DE:AFX)
XETRA:AFX
Holding DE:AFX?
Track your performance easily

Carl Zeiss Meditec (AFX) Income Statement

72 Followers

Carl Zeiss Meditec Income Statement

Last quarter (Q1 2023), Carl Zeiss Meditec's total revenue was €470.30M, an increase of 4.84% from the same quarter last year. In Q1, Carl Zeiss Meditec's net income was €51.00M. See Carl Zeiss Meditec’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Sep 23Sep 22Sep 21Sep 20Sep 19
Total Revenue
€ 1.80B€ 2.09B€ 1.90B€ 1.65B€ 1.34B€ 1.46B
Cost of Revenue
€ 787.50M-€ 775.24M€ 679.57M€ 589.93M€ 627.44M
Gross Profit
€ 1.04B-€ 1.13B€ 967.21M€ 745.52M€ 831.88M
Operating Expense
€ 706.39M-€ 730.72M€ 593.60M€ 567.97M€ 567.23M
Operating Income
€ 336.23M-€ 396.88M€ 373.61M€ 177.55M€ 264.66M
Net Non Operating Interest Income Expense
€ 30.33M-€ 55.24M€ -9.46M€ -3.29M€ -6.15M
Other Income Expense
------
Pretax Income
€ 335.53M-€ 403.49M€ 339.05M€ 178.72M€ 229.86M
Tax Provision
€ 92.94M-€ 107.58M€ 101.53M€ 55.30M€ 69.28M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
€ 242.16M-€ 293.91M€ 236.28M€ 122.39M€ 159.76M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
€ 1.49B-€ 1.51B€ 1.27B€ 1.16B€ 1.19B
Net Income From Continuing And Discontinued Operation
€ 242.16M-€ 293.91M€ 236.28M€ 122.39M€ 159.76M
Normalized Income
€ 242.16M-€ 293.91M€ 236.28M€ 122.39M€ 159.76M
Interest Expense
€ 9.19M-€ 9.59M€ 9.37M€ 27.89M€ 8.21M
EBIT
€ 344.72M-€ 413.08M€ 348.42M€ 206.60M€ 238.07M
EBITDA
€ 344.72M€ 501.88M€ 482.85M€ 410.00M€ 267.03M€ 286.44M
Currency in EUR

Carl Zeiss Meditec Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis